Main Strategies of Plant Expression System Glycoengineering for Producing Humanized Recombinant Pharmaceutical Proteins


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Most the pharmaceutical proteins are derived not from their natural sources, rather their recombinant analogs are synthesized in various expression systems. Plant expression systems, unlike mammalian cell cultures, combine simplicity and low cost of procaryotic systems and the ability for posttranslational modifications inherent in eucaryotes. More than 50% of all human proteins and more than 40% of the currently used pharmaceutical proteins are glycosylated, that is, they are glycoproteins, and their biological activity, pharmacodynamics, and immunogenicity depend on the correct glycosylation pattern. This review examines in detail the similarities and differences between N- and O–glycosylation in plant and mammalian cells, as well as the effect of plant glycans on the activity, pharmacokinetics, immunity, and intensity of biosynthesis of pharmaceutical proteins. The main current strategies of glycoengineering of plant expression systems aimed at obtaining fully humanized proteins for pharmaceutical application are summarized.

作者简介

S. Rozov

Federal Research Center Institute of Cytology and Genetics; Novosibirsk State University

编辑信件的主要联系方式.
Email: rozov@bionet.nsc.ru
俄罗斯联邦, Novosibirsk, 630090; Novosibirsk, 630090

N. Permyakova

Federal Research Center Institute of Cytology and Genetics

Email: rozov@bionet.nsc.ru
俄罗斯联邦, Novosibirsk, 630090

E. Deineko

Federal Research Center Institute of Cytology and Genetics; National Tomsk State University

Email: rozov@bionet.nsc.ru
俄罗斯联邦, Novosibirsk, 630090; Tomsk, 634050


版权所有 © Pleiades Publishing, Ltd., 2018
##common.cookie##